Literature DB >> 3814477

Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.

M R Williams, J H Todd, I O Ellis, C S Dowle, J L Haybittle, C W Elston, R I Nicholson, K Griffiths, R W Blamey.   

Abstract

ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and subsequent response to endocrine therapy. A significant advantage in terms of survival is found in ER positive patients which is confined to those lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive patients. Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is prolonged in patients with ER positive tumours. The overall response rate to endocrine therapy in assessable patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER positive, grade I and II) with a response rate of 46%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814477      PMCID: PMC2001565          DOI: 10.1038/bjc.1987.14

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland.

Authors:  J L Hayward; P P Carbone; J C Heuson; S Kumaoka; A Segaloff; R D Rubens
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

2.  Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer.

Authors:  J C Allegra; M E Lippman; E B Thompson; R Simon; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  Eur J Cancer       Date:  1980-03       Impact factor: 9.162

3.  Association between steroid hormone receptor status and disease-free interval in breast cancer.

Authors:  J C Allegra; M E Lippman; R Simon; E B Thompson; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  Cancer Treat Rep       Date:  1979-08

4.  Estrogen receptor assay in primary breast cancer and early recurrence of the disease.

Authors:  P V Maynard; R W Blamey; C W Elston; J L Haybittle; K Griffiths
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

5.  The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer.

Authors:  R Hilf; M L Feldstein; S L Gibson; E D Savlov
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

6.  Oestrogen receptors and prognosis in early breast cancer.

Authors:  T Cooke; D George; R Shields; P Maynard; K Griffiths
Journal:  Lancet       Date:  1979-05-12       Impact factor: 79.321

7.  Relationship of oestrogen-receptor status to survival in breast cancer.

Authors:  H M Bishop; R W Blamey; C W Elston; J L Haybittle; R I Nicholson; K Griffiths
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

8.  Response to endocrine therapy and breast cancer differentiation.

Authors:  J R Masters; R R Millis; R D Rubens
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

9.  Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.

Authors:  M M Roberts; R D Rubens; R J King; R A Hawkins; R R Millis; J L Hayward; A P Forrest
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

10.  Relationship between oestrogen-receptor content and histological grade in human primary breast tumours.

Authors:  P V Maynard; C J Davies; R W Blamey; C W Elston; J Johnson; K Griffiths
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

View more
  18 in total

1.  The Nottingham Prognostic Index in primary breast cancer.

Authors:  M H Galea; R W Blamey; C E Elston; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?

Authors:  Sunil R Lakhani; Kum Kum Khanna; Georgia Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2010-03-19       Impact factor: 6.466

3.  Node negative breast cancer.

Authors:  R W Blamey; C W Elston; I O Ellis; D A Morgan; J L Haybittle
Journal:  BMJ       Date:  1990-04-28

4.  Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters.

Authors:  M Helle; M Helin; J Isola; H Helin
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  Development and validation of a sensitive immunohistochemical oestrogen receptor assay for use on archival breast cancer tissue.

Authors:  P Jackson; J Teasdale; P N Cowen
Journal:  Histochemistry       Date:  1989

6.  Prediction of nodal spread of breast cancer by using artificial neural network-based analyses of S100A4, nm23 and steroid receptor expression.

Authors:  S R Grey; S S Dlay; B E Leone; F Cajone; G V Sherbet
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

7.  Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods.

Authors:  T A Aasmundstad; O A Haugen; E Johannesen; A L Høe; S Kvinnsland
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

8.  Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods.

Authors:  A Molino; R Micciolo; M Turazza; F Bonetti; Q Piubello; A Corgnati; L Sperotto; G Martignoni; A Bonetti; R Nortilli
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

9.  Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor.

Authors:  H Htun; L T Holth; D Walker; J R Davie; G L Hager
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

10.  Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy.

Authors:  J F Robertson; A R Dixon; R I Nicholson; I O Ellis; C W Elston; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.